FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Nadolol and Bendroflumethiazide Tablets
Status: Discontinuation
»Therapeutic Categories: Cardiovascular

Expand all

Impax Laboratories (New 08/25/2017)

Company Contact Information:
877-994-6729

Presentation Posting Date Related Information
40 mg/5 mg; 100 tablets/bottle (NDC 0115-5311-01) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.
40 mg/5 mg; 500 tablets/bottle (NDC 0115-5311-02) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.
80 mg/5 mg; 100 tablets/bottle (NDC 0115-5322-01) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.
80 mg/5 mg; 500 tablets/bottle (NDC 0115-5322-02) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English